 |  |  |  |  |  |  |  |  |  |  |  |  |  |

  |
Advanced Master in Industrial Pharmacy
 |
Th
 |
Pr
 |
Au
 | Credits
 |
 A single year
 |
 Compulsory courses
 |
| 
PHIN2004-1
 | 
Active substances
 |
 |
 |
 | 6
 |
| | 
- Substances issues de recherches pharmacochimiques, part a - Bernard Pirotte
 | 10
 | -
 | -
 | |
| | 
- Substances issues de recherches pharmacochimiques, part b - Françoise Dufrasne
 | 5
 | -
 | -
 | |
| | 
- Substances issues des biotechnologies - Jean‑Paul Dehaye
 | 15
 | -
 | -
 | |
| | 
- Substances d'origine naturelle, part a - Joëlle Quetin‑Leclercq
 | 5
 | -
 | -
 | |
| | 
- Substances d'origine naturelle, part b - Pierre Duez
 | 5
 | -
 | -
 | |
| | 
- Produits radiopharmaceutiques - Ghanem Ghanem
 | 10
 | -
 | -
 | |
| 
PHIN2008-1
 | 
Clinical viewpoints
 |
 |
 |
 | 6
 |
| | 
- Métabolisme des médicaments et paramètres pharmacocinétiques - Roger Verbeek
 | 20
 | -
 | -
 | |
| | 
- Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - André Scheen
 | 20
 | -
 | -
 | |
| | 
- Information et pharmacovigilance - Corinne Charlier, Raphaël Denooz
 | 10
 | -
 | -
 | |
| 
PHIN2013-1
 | 
Quality assurance and pharmaceutical management
 |
 |
 |
 | 8
 |
| | 
- Economic aspects of drug development - Dominique Martin
 | 10
 | -
 | -
 | |
| | 
- Principles of pharmaceutical management - Jean‑Michel Van Der Hofstadt
 | 10
 | -
 | -
 | |
| | 
- Quality assurance, part a : basic concepts and quality assurance organisation - Jean Scouvart
 | 20
 | -
 | -
 | |
| | 
- Quality assurance, part b : Analytical technology of procedures and risk analysis - Xavier Marcelis
 | 7,5
 | -
 | -
 | |
| | 
- English applied to the pharmaceutical industry - Didier Lambert, Nevin Serbest
 | 20
 | -
 | -
 | |
| | 
- Pharmaceutical marketing - Vincent Bierlaire
 | 7,5
 | -
 | -
 | |
| 
PHIN2022-1
 | 
Industrial pharmaceutical technology
 |
 |
 |
 | 8
 |
| | 
- Microbiologie pharmaceutique industrielle - Véronique Fontaine
 | 15
 | -
 | -
 | |
| | 
- Préformulation et sélection des formes galéniques - Karim Amighi
 | 15
 | -
 | -
 | |
| | 
- Production industrielle des formes galéniques - Brigitte Evrard
 | 15
 | -
 | -
 | |
| | 
- Génie pharmaceutique - Jean Gillard
 | 15
 | -
 | -
 | |
| | 
- Aspects industriels du développement technologique y compris le conditionnement - Laurence Denis
 | 10
 | -
 | -
 | |
| 
PHIN2023-2
 | 
Drug analysis
 |
 |
 |
 | 7
 |
| | 
- Pratique des méthodes d'analyse et de contrôle pharmaceutique et biopharmaceutique, part a - Pierre Van Antwerpen
 | 10
 | -
 | -
 | |
| | 
- Pratique des méthodes d'analyse et de contrôle pharmaceutique et biopharmaceutique, part b - Marianne Fillet
 | 10
 | -
 | -
 | |
| | 
- Validation des méthodes d'analyse pharmaceutique et biopharmaceutique, qualification de l'appareillage et préparation des échantillons pharmaceutiques - Philippe Hubert
 | 20
 | -
 | -
 | |
| | 
- Méthodes statistiques appliquées à l'industrie pharmaceutique - N...
 | 15
 | -
 | -
 | |
| | 
- Planification expérimentale - Bruno Boulanger
 | 10
 | -
 | -
 | |
| 
PHIN2029-1
 | 
Regulation and the medical-social environment
 |
 |
 |
 | 7
 |
| | 
- Legislation and procedures applied to pharmaceutical industry, part a : legislation - Catherine Druez
 | 10
 | 5
 | -
 | |
| | 
- Legislation and procedures applied to pharmaceutical industry, part b : patents and protection - Sylvie Ponchaut
 | 5
 | -
 | -
 | |
| | 
- Economic and medical social medicine - Alain De Wever
 | 10
 | -
 | -
 | |
| | 
- CTD File (Common Technical Document) - Jean‑Antoine De Muylder
 | 15
 | -
 | -
 | |
| | 
- Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files - Sonia Beken
 | 15
 | -
 | -
 | |
| | 
- Regulations of preclinical and clinical studies, part b : clinical studies - A Lenaers
 | 5
 | -
 | -
 | |
| | 
- Regulations of preclinical and clinical studies, part c : pediatric studies - Daniel Brasseur
 | 2,5
 | -
 | -
 | |
| | 
- Specific regulatory issues, part a : medicine and herbal dietary supplement - Monique Tits
 | 5
 | -
 | -
 | |
| | 
- Specific regulatory issues, part a : galenic developement - Francis Vanderbist
 | 5
 | -
 | -
 | |
| 
MTFE2000-1
 | 
Final work - Collégialité
 | -
 | -
 | -
 | 18
 |
| 
 |
| 
Visits and seminars will be organised in pharmaceutical industries.
 |